Abstract | INTRODUCTION: METHODS: RESULTS: The median age was 42 years, 62.5% were male, and 79.5% were Asian. One hundred thirty-two (31.4%) patients had FLD (77 [18.3%] steatosis only, 55 [13.1%] steatohepatitis). Older age, overweight/ obesity, and diabetes were associated with steatohepatitis. Steatohepatitis (vs no FLD) was associated with 1.68 times higher risk of advanced fibrosis at baseline (95% confidence interval, 1.12-2.51), and there was an indication of higher incident cirrhosis rate during follow-up. Steatohepatitis vs no FLD was also independently associated with, on average, 1.39 times higher alanine aminotransferase (P < 0.01) and 1.25 times higher Fibrosis-4 (P = 0.04) across 4 years. DISCUSSION: Coexisting steatosis occurred in nearly a third of adults (13% had steatohepatitis) with chronic HBV in this North American cohort who underwent liver biopsies. Steatohepatitis was associated with advanced fibrosis and higher biochemical measures of hepatic inflammation over time. Therefore, in addition to viral suppression, screening for and managing metabolic abnormalities is important to prevent disease progression in HBV.
|
Authors | Mandana Khalili, David E Kleiner, Wendy C King, Richard K Sterling, Marc G Ghany, Raymond T Chung, Atul K Bhan, Philip Rosenthal, Mauricio Lisker-Melman, Rageshree Ramachandran, Anna S Lok, ; and the Hepatitis B Research Network (HBRN) |
Journal | The American journal of gastroenterology
(Am J Gastroenterol)
Vol. 116
Issue 8
Pg. 1686-1697
(08 01 2021)
ISSN: 1572-0241 [Electronic] United States |
PMID | 33840726
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural)
|
Copyright | Copyright © 2021 by The American College of Gastroenterology. |
Topics |
- Adolescent
- Adult
- Age Factors
- Aged
- Biopsy
- Disease Progression
- Fatty Liver
(complications, epidemiology)
- Female
- Hepatitis B, Chronic
(complications)
- Humans
- Male
- Middle Aged
- North America
(epidemiology)
- Risk Factors
|